
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor V CRISPR Activation Plasmid (h) | sc-404180-ACT | 20 µg | $397.00 |
Human F5 encodes coagulation Factor V, a plasma glycoprotein that functions as a critical cofactor in the prothrombinase complex to accelerate thrombin generation during the common pathway of the coagulation cascade. Upon activation to Factor Va, it assembles with Factor Xa on phospholipid membranes in a calcium-dependent manner, amplifying clot formation and linking platelet surface biology to fibrin production. Factor V activity is tightly regulated by proteolytic inactivation and anticoagulant pathways, including modulation by activated protein C. Genetic variation or dysregulated expression of F5 is associated with altered hemostatic balance and is widely studied in thrombotic and bleeding disorder biology.
Factor V CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous F5 expression without altering the underlying DNA sequence.
Factor V CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the F5 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the F5 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Factor V expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native F5 locus and enabling the study of Factor V-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Factor V pathway restoration in tumor cells with silenced or reduced F5 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.